Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →
Johnson & Johnson
JNJHealthcareGenerated Jul 5, 2026, 08:13 PM UTC
JNJ (Johnson & Johnson) analytical snapshot. Net income up ▲ +95.9% YoY. Debt/equity 0.51, current ratio 1.03, net debt $19.75B. Market cap $633.19B at $263.04 per share. Trailing P/E 19.17, P/B 7.80. EV/Operating income ≈ 43.66 (EV $652.94B). Risk: Moderate. Macro: Risk-on · Supportive. Composite analytical score -7 (data confidence 78%). Descriptive analytics from public filings — not investment advice.
Market cap
$633.19B
2.41B shares
Price
$263.04
NYQ
P/E (ttm)
19.17
Revenue (FY)
—
Net margin
—
Free cash flow
$18.25B
Risk level
Moderate
Free SEC analysis
— computed from SEC filings, free to readFree previewFundamentals Analyst
Fundamentals
Fundamentals Analyst
score 0Stable
80% conf
Net income up ▲ +95.9% YoY. Debt/equity 0.51, current ratio 1.03, net debt $19.75B.
- Net income up ▲ +95.9% YoY.
- Debt/equity 0.51, current ratio 1.03, net debt $19.75B.
Revenue (FY)
—
Net margin
—
ROE
—
ROA 19.52%
ROIC
0.00%
EPS (diluted)
$13.72
FY2025
Free cash flow
$18.25B
Debt / equity
0.51
Cash $21.69B
Current ratio
1.03
Equity $81.19B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | — | — | — | — | — | $15.00B | — |
| 2017 | — | — | — | — | — | $16.11B | — |
| 2018 | — | — | — | — | — | $15.54B | — |
| 2019 | — | — | — | — | — | $17.78B | — |
| 2020 | — | — | — | — | — | $18.53B | — |
| 2021 | — | — | — | — | — | $19.92B | — |
| 2022 | — | — | — | — | — | $20.19B | — |
| 2023 | — | — | — | — | — | $19.76B | — |
| 2024 | — | — | — | — | — | $17.18B | — |
| 2025 | — | — | — | — | — | $18.25B | — |
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Sep 29, 2013 | $17.57B | — | — | 58.67% |
| Mar 30, 2014 | $18.11B | — | +3.1% | 26.09% |
| Jun 29, 2014 | $37.61B | — | +107.6% | 24.07% |
| Jun 29, 2014 | $19.50B | — | -48.2% | 46.44% |
| Sep 28, 2014 | $56.08B | — | +187.6% | 24.61% |
| Sep 28, 2014 | $18.47B | — | -67.1% | 74.74% |
Free cash flow (annual)
2016: 14,996
2017: 16,106
2018: 15,541
2019: 17,777
2020: 18,531
2021: 19,918
2022: 20,189
2023: 19,758
2024: 17,185
2025: 18,248
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sources:SEC EDGAR — Company Facts (XBRL)
Free previewRegulatory Analyst
Filings & Ownership
Regulatory Analyst
score 30Improving
80% conf
Latest annual report (10-K) filed Feb 11, 2026. Latest quarterly report (10-Q) filed Apr 22, 2026. 7 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 11, 2026.
- Latest quarterly report (10-Q) filed Apr 22, 2026.
- 7 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Johnson & Johnson; broad institutional reporting.
- Recent filers include LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA.
- 9 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 11 recent 13G passive institutional ownership notices.
Latest 10-K
Feb 11, 2026
Annual report
Latest 10-Q
Apr 22, 2026
8-K (recent)
7
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
9
Recent 13F institutional filers (SEC EDGAR full-text)
| Filer | Form | Filed |
|---|---|---|
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | May 15, 2003 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Aug 9, 2002 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | May 8, 2001 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | May 11, 2004 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Nov 2, 2001 |
Recent 8-K material events
| Date | Form | Description |
|---|---|---|
| Apr 28, 2026 | 8-K | 8-K |
| Apr 14, 2026 | 8-K | 8-K |
| Jan 21, 2026 | 8-K | 8-K |
| Oct 14, 2025 | 8-K | 8-K |
| Sep 9, 2025 | 8-K | 8-K |
| Jul 16, 2025 | 8-K | 8-K |
| Jun 10, 2025 | 8-K | 8-K |
Free previewSEC Filing Analyst
SEC Filing Deep-Analysis
SEC Filing Analyst
score -45Deteriorating
68% conf
3 risk signal(s) detected from XBRL filing diff analysis. 3 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- NEW: Going concern doubt in latest filing: The term "going concern" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 10 filing(s).
- Material weakness in internal controls: The term "material weakness" appears in 19 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- NEW: Substantial doubt about ability to continue in latest filing: The term "substantial doubt" "ability to continue" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 10 filing(s).
- Endogenous analysis: 3 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 2 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 2 new risk-language term(s) detected in filing text: Going concern doubt, Substantial doubt about ability to continue.
- Ongoing high-severity risk language: Material weakness in internal controls.
Gross profit
$58.61B
+5.8% YoY
Operating income
$14.96B
+8.6% YoY
Net income
$35.15B
+95.9% YoY
Operating cash flow
$22.79B
+7.5% YoY
Capex
$4.54B
+13.3% YoY
Total assets
$180.10B
+7.5% YoY
Total liabilities
$108.61B
+10.0% YoY
Long-term debt
$32.40B
+18.5% YoY
Filing quality score
74/100
2 new disclosures
SEC XBRL metric changes (latest annual vs prior)
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Gross profit | $55.39B | $58.61B | $3.21B | +5.8% |
| Operating income | $13.77B | $14.96B | $1.19B | +8.6% |
| Net income | $17.94B | $35.15B | $17.21B | +95.9% |
| Operating cash flow | $21.19B | $22.79B | $1.60B | +7.5% |
| Capex | $4.01B | $4.54B | $534.0M | +13.3% |
| Total assets | $167.56B | $180.10B | $12.55B | +7.5% |
| Total liabilities | $98.78B | $108.61B | $9.83B | +10.0% |
| Long-term debt | $27.35B | $32.40B | $5.05B | +18.5% |
| Cash & equivalents | $21.86B | $24.11B | $2.25B | +10.3% |
| Inventory | $11.18B | $12.44B | $1.26B | +11.3% |
| Accounts receivable | $14.87B | $14.84B | $-31.0M | -0.2% |
| R&D expense | $0 | $483.0M | $483.0M | — |
| SG&A expense | $20.25B | $21.51B | $1.27B | +6.3% |
| Interest expense | $201.0M | $183.0M | $-18.0M | -9.0% |
XBRL disclosure changes (new vs dropped concepts)
| Type | Concepts |
|---|---|
| Added | LossContingencyNumberOfPlaintiffs, PaymentsForLegalSettlements |
| Removed | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue, AdvertisingExpense, AllocatedShareBasedCompensationExpense, BusinessCombinationAcquisitionRelatedCosts, BusinessCombinationConsiderationTransferredLiabilitiesIncurred, CapitalExpenditureDiscontinuedOperations, CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations, CommercialPaper, ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest, CurrentFederalTaxExpenseBenefit |
Risk language in filing text (EDGAR full-text search)
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Going concern doubt | high | 10 | 0 | NEW |
| Material weakness in internal controls | high | 19 | 2 | Ongoing |
| Substantial doubt about ability to continue | high | 10 | 0 | NEW |
| Impairment charge | medium | 46 | 8 | Ongoing |
| Restructuring | medium | 86 | 8 | Ongoing |
| Related party transactions | low | 13 | 5 | Ongoing |
Filing signal breakdown
Red flags: 3
Positive: 0
Watch: 0
Red flags
Positive
Watch
Unlock the rest
- ProValuationMarket cap $633.19B at $263.04 per share.
- ProPrice & TechnicalsPrice $263.04 — uptrend (above 200-DMA); 1-month momentum positive.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Moderate.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite -7
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Johnson & Johnson is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
16.59
Fed funds
3.63%
CPI YoY
+4.2%
Analytical read
deterministic previewPrice $263.04 — uptrend (above 200-DMA); 1-month momentum positive..
Risk
Moderate
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Peer comparison
Defensive groupHow JNJ stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Intuitive Surgical Inc. ISRG | -1 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ● you | -7 | Neutral |
| Danaher Corp. DHR | -11 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| HCA Healthcare HCA | -14 | Neutral |
| Illumina Inc. ILMN | -16 | Neutral |
| Kroger Co. KR | -16 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |
| Thermo Fisher Scientific TMO | — | Neutral |
| Vertex Pharmaceuticals VRTX | — | Neutral |
| Gilead Sciences GILD | — | Neutral |
| Zoetis Inc. ZTS | — | Neutral |
| Kimberly-Clark Corp. KMB | — | Neutral |
| Hershey Co. HSY | — | Neutral |
| Sysco Corp. SYY | — | Neutral |
| Moderna Inc. MRNA | — | Neutral |
| Biogen Inc. BIIB | — | Neutral |
| DexCom Inc. DXCM | — | Neutral |